Imatinib Mesylate Capsules :-
Gleevec (also known as imatinib mesylate, STI571) is a drug that has been specifically developed to treat cancer by blocking an enzyme that causes cells to become cancerous and multiply.
Health Canada has issued a conditional marketing authorization under a policy called the "Notice of Compliance with Conditions" (NOC/c) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia (CML). This approval was based on the promising nature of the clinical evidence which must be confirmed and extended with further studies.
This current conditional approval for Gleevec is for adult patients with newly diagnosed CML.
Previous Conditional approvals for Gleevec are for adult patients with: